Safety of inhaled long-acting anti-muscarinic agents in COPD
NA Hanania, SC Lareau, BP Yawn - Postgraduate Medicine, 2017 - Taylor & Francis
Evidence-based guidelines recommend inhaled long-acting anti-muscarinic agents
(LAMAs) as first-line maintenance therapy for symptomatic patients with COPD. Several …
(LAMAs) as first-line maintenance therapy for symptomatic patients with COPD. Several …
Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment
N Roche, G Jebrak, D Caillaud… - European …, 2015 - Eur Respiratory Soc
Chronic obstructive pulmonary disease (COPD) pharmacological treatment aims to reduce
symptoms, represented mostly by dyspnoea and its impact on daily life, and future risk, ie …
symptoms, represented mostly by dyspnoea and its impact on daily life, and future risk, ie …
Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators
NS Skolnik, TS Nguyen, A Shrestha, R Ray… - Postgraduate …, 2020 - Taylor & Francis
Long-acting inhaled bronchodilator medications are recommended as initial maintenance
therapy for many patients with COPD. These medications include long-acting muscarinic …
therapy for many patients with COPD. These medications include long-acting muscarinic …
Long-acting muscarinic antagonist versus inhaled corticosteroid when added to long-acting β-agonist for COPD: a meta-analysis
Y Oba, AV Chandran… - COPD: Journal of Chronic …, 2016 - Taylor & Francis
The purpose of this study was to systematically review the efficacy and safety of long-acting
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …
Is combination long-acting beta-agonist and long-acting muscarinic antagonist therapy the future of COPD therapy?
MJ Alexander, D Zappetti - Clinical Pulmonary Medicine, 2016 - journals.lww.com
A large, randomized, double-blind, multicenter, noninferiority trial revealed consistent
superiority in exacerbation reduction, functional respiratory improvement, and quality-of-life …
superiority in exacerbation reduction, functional respiratory improvement, and quality-of-life …
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
MIA Aziz, LE Tan, DBC Wu, F Pearce… - … journal of chronic …, 2018 - Taylor & Francis
Purpose To assess the comparative efficacy of short-acting muscarinic antagonists (SAMAs),
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …
Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
SE Petite - Annals of Pharmacotherapy, 2017 - journals.sagepub.com
Objective: To compare the available literature regarding the use of long-acting muscarinic
antagonist (LAMA)/long-acting β2 agonists (LABA) and inhaled corticosteroid (ICS)/LABA …
antagonist (LAMA)/long-acting β2 agonists (LABA) and inhaled corticosteroid (ICS)/LABA …
Long‐acting beta2‐agonists versus long‐acting muscarinic antagonists in patients with stable COPD: a systematic review and meta‐analysis of randomized controlled …
WC Chen, CH Huang, CC Sheu, IW Chong… - …, 2017 - Wiley Online Library
Several long‐acting bronchodilators have been developed and are widely used as first‐line
treatment in patients with stable chronic obstructive pulmonary disease (COPD). However …
treatment in patients with stable chronic obstructive pulmonary disease (COPD). However …
Long‐acting muscarinic antagonist+ long‐acting beta agonist versus long‐acting beta agonist+ inhaled corticosteroid for COPD: a systematic review and meta …
N Horita, N Miyazawa, K Tomaru, M Inoue… - …, 2015 - Wiley Online Library
Some trials have been conducted to compare long‐acting muscarinic antagonist (LAMA)+
long‐acting beta agonist (LABA) versus LABA+ inhaled corticosteroids (ICS) for chronic …
long‐acting beta agonist (LABA) versus LABA+ inhaled corticosteroids (ICS) for chronic …
Use of ICS in COPD: from blockbuster medicine to precision medicine
M Contoli, AG Corsico, P Santus… - COPD: Journal of …, 2017 - Taylor & Francis
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide,
whose burden is expected to increase in the next decades, because of numerous risk …
whose burden is expected to increase in the next decades, because of numerous risk …